Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Charles S. Hesdorffer"'
Autor:
Pia Nierman, Erika M Gaglione, Inhye E. Ahn, Jennifer Lotter, Mir A. Ali, Jeffrey I. Cohen, Gerald E. Marti, Susan Soto, Adrian Wiestner, Jeanine Superata, Clare Sun, Charles S. Hesdorffer, Christopher Pleyer, Xin Tian
Publikováno v:
Blood
Publisher's Note: There is a Blood Commentary on this article in this issue.
Key Points De novo immune response to hepatitis B vaccine was nearly absent in CLL patients on BTKi and impaired in treatment-naïve patients. Recall immune response to
Key Points De novo immune response to hepatitis B vaccine was nearly absent in CLL patients on BTKi and impaired in treatment-naïve patients. Recall immune response to
Autor:
Amy Tiersten, Linda T. Vahdat, Dawn L. Hershman, David G. Savage, Charles S. Hesdorffer, I. Wertheim, R.B. Macarthur, Elizabeth L. Kaufman, M. Selleck, D.H. Smith
Publikováno v:
International Journal of Gynecological Cancer. 16:57-64
The objectives of this study were to investigate the tolerability of a novel high-dose chemotherapy (HDC) regimen with peripheral blood progenitor cell (PBPC) support in patients with pretreated advanced ovarian cancer and to determine the maximum-to
Autor:
Charles S. Hesdorffer, Donna Skerrett, L Wiebe, Kyriakos P. Papadopoulos, D Bernstein, K M S Lo, James Garvin, L H Vahdat, W Noguera-Irizarry, E Sharpe, Gwen Nichols, David G. Savage
Publikováno v:
Bone Marrow Transplantation. 36:491-497
In an effort to improve the outcome of poor-risk lymphoma patients, we evaluated a novel regimen of tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation. A total of 41 patients (median age 40 years, range 15-68 years) with p
Autor:
Andrea Merlo, Stefan Stevanovic, Lloyd J. Old, Donata Rimoldi, Yao-Tseng Chen, Daniel E. Speiser, Charles S. Hesdorffer, Maha Ayyoub, Jean Charles Cerottini, Danila Valmori
Publikováno v:
The Journal of Immunology. 174:5092-5099
Genes of the synovial sarcoma X breakpoint (SSX) family are expressed in different human tumors, including melanomas, but not in adult somatic tissues. Because of their specific expression at the tumor site, SSX-encoded Ags are potential targets for
Autor:
Karl S. Hurst-Wicker, and Howard L. Kaufman, Kenneth Cheung, Charles S. Hesdorffer, John P. Stoutenburg, Gail DeRaffele Rn, Kathryn Spanknebel
Publikováno v:
Annals of Surgical Oncology. 12:381-390
Background High-dose interleukin (IL)-2 is an effective agent for the treatment of metastatic malignant melanoma and renal cell carcinoma. This study evaluated the outcomes of patients receiving two commonly used intravenous IL-2 schedules that have
Autor:
Maha Ayyoub, Danila Valmori, Andrea Merlo, Donata Rimoldi, Gerd Ritter, Yao-Tseng Chen, Lloyd J. Old, Stefan Stevanovic, Charles S. Hesdorffer, Daniel E. Speiser, Jean Charles Cerottini
Publikováno v:
Clinical Immunology. 114:70-78
Because of their specific expression in tumors of different histological types, the products of the SSX genes are important candidate targets for development of cancer vaccines. We have previously identified two immunodominant SSX-2-derived T cell ep
Autor:
Andrea Troxel, Aaron Weitzman, Jennifer Y. Wo, Amy Tiersten, Charles S. Hesdorffer, Caron A. Jacobson, Tamara B. Horwich, David G. Savage
Publikováno v:
The Breast. 13:341-346
Introduction: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy. Study design: We combined paclitaxel, melphalan and hig
Autor:
Dennis Panicali, Kathryn Spanknebel, Howard L. Kaufman, Ziv Haskall, Charles S. Hesdorffer, Heidi Hörig, Gail DeRaffele, Kenneth Cheung
Publikováno v:
Human Gene Therapy. 14:803-827
Autor:
Anthony W. Ferrante, Richard P. Catanzaro, Brygida Bisikirska, James M. McKiernan, Paul L. Harris, Federica Moschella, Ihor S. Sawczuk, Antonella Maffei, Kyriakos P. Papadapoulos, Charles S. Hesdorffer
Publikováno v:
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 14:133-145
The use of cultured tumor cells rather than original tumor tissue for the preparation of therapeutic cancer vaccines represents an obvious solution to the problem of availability of adequate quantities of autologous tumor. In this study we investigat
Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
Autor:
Danila Valmori, Robert N. Taub, Philippe Guillaume, Paul L. Harris, Jean Charles Cerottini, Charles S. Hesdorffer, Valérie Dutoit, Lloyd J. Old, Sacha Gnjatic, Brygida Bisikirska, Kyriakos P. Papadopoulos, Michelle Brehm, Mary Louise Keohan, Susan Talbot
Publikováno v:
Journal of Clinical Investigation. 110:1813-1822
The cancer-testis antigen NY-ESO-1 is one of the most promising candidates for generic vaccination of cancer patients. Here we analyzed the CD8+ T cell response to a NY-ESO-1 peptide vaccine composed of the two previously defined peptides 157-165 and